This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have spread to other places in the body and have come back or do not respond to treatment with FGFR mutations. Erdafitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Principal Investigator
Anne-Marie Langevin
Jaclyn Hung
+1 (210) 450-5358
hungj@uthscsa.edu
Arm | Description | Intervention |
---|---|---|
Treatment (erdafitinib) | Patients receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. | Correlative studies Given PO Other names:
Correlative studies |